Urinary tract infections (UTIs) present a formidable challenge in the care of individuals affected by multiple sclerosis (MS). Lower urinary tract dysfunction is a prevalent issue among MS patients, predisposing them to an elevated risk of UTIs. When left untreated, UTIs can further exacerbate the already compromised quality of life in individuals with MS. The diagnosis and management of UTIs in MS patients necessitate a careful clinical evaluation. The objective of this review is to delineate preventive strategies and current and developing therapeutic approaches for preventing and treating UTIs associated with urinary dysfunction, catheterization, and upper urinary tract infections in patients with MS. Effectively addressing UTIs and urinary tract dysfunction in individuals with multiple sclerosis calls for a comprehensive, interdisciplinary approach.
ThompsonAJBaranziniSEGeurtsJ, et al. Multiple sclerosis. Lancet2018; 391(10130): 1622–1636.
2.
Koch-HenriksenNMagyariM. Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol2021; 17(11): 676–688.
3.
FilomenaGBGentileBCAlbanesiL, et al. Long-term outcomes following bipolar transurethral plasma enucleation of the prostate: 10-year follow-up. J Endourol2023; 37(7): 811–816.
4.
Katz SandI. Classification, diagnosis, and differential diagnosis of multiple sclerosis. Curr Opin Neurol2015; 28(3): 193–205.
5.
JickSSLiLFalconeGJ, et al. Epidemiology of multiple sclerosis: results from a large observational study in the UK. J Neurol2015; 262(9): 2033–2041.
6.
FowlerCJvan KerrebroeckPENordenboA, et al. Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. Committee of the European Study Group of SUDIMS (Sexual and Urological Disorders in Multiple Sclerosis). J Neurol Neurosurg Psychiatry1992; 55(11): 986–989.
7.
PheVChartier-KastlerEPanickerJN. Management of neurogenic bladder in patients with multiple sclerosis. Nature reviews. Urology2016; 13(5): 275–288.
8.
LitwillerSEFrohmanEMZimmernPE. Multiple sclerosis and the urologist. J Urol1999; 161(3): 743–757.
9.
BientinesiR.CampetellaM., et al. Identification of brain structures involved in lower urinary tract symptoms and sexual dysfunctions in patients with multiple sclerosis. Glob J Med Res2021; XXI(II), I: 42–48.
10.
YangCC. Bladder management in multiple sclerosis. Phys Med Rehabil Clin N Am2013; 24(4): 673–686.
11.
WintnerAKimMMBechisSK, et al. Voiding dysfunction in multiple sclerosis. Semin Neurol2016; 36(1): 34–40.
12.
MoraschiMDiNuzzoMGioveF. On the origin of sustained negative BOLD response. J Neurophysiol2012; 108(9): 2339–2342.
13.
MaghziAHMinagarA.Urinary tract infection in multiple sclerosis: a practical algorithm for a common problem. Eur J Neurol2013; 20(3): 408–409.
14.
Salinas-CasadoJVirseda-ChamorroMMéndez-RubioS, et al. Clinical and urodynamic risk factors of recurrent urinary tract infections in patients with multiple sclerosis. Arch Esp Urol2019; 72: 1010–1017.
15.
Esclarín De RuzAGarcía LeoniEHerruzo CabreraR. Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol2000; 164(4): 1285–1289.
16.
RakusaMMurphyOMcIntyreL, et al. Testing for urinary tract colonization before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm valid. Eur J Neurol2013; 20(3): 448–452.
17.
PloypetchTDajprathamPAssanasenS, et al. Epidemiology of urinary tract infection among spinal cord injured patients in rehabilitation ward at Siriraj Hospital. J Med Assoc Thai2013; 96: 99–106.
18.
HossainJMorandiETanasescuR, et al. The soluble form of toll-like receptor 2 is elevated in serum of multiple sclerosis patients: a novel potential disease biomarker. Front Immunol2018; 9: 457.
19.
PerssonRLeeSUlcickas YoodM, et al. Infections in patients diagnosed with multiple sclerosis: a multi-database study. Mult Scler Relat Disord2020; 41: 101982.
20.
PhéVPakzadMCurtisC, et al. Urinary tract infections in multiple sclerosis. Mult Scler2016; 22(7): 855–861.
21.
MahadevaATanasescuRGranB. Urinary tract infections in multiple sclerosis: under-diagnosed and under-treated? A clinical audit at a large University Hospital. Am J Clin Exp Immunol2014; 3(1): 57–67.
22.
BalsaraZRRossSSDolberPC, et al. Enhanced susceptibility to urinary tract infection in the spinal cord-injured host with neurogenic bladder. Infect Immun2013; 81(8): 3018–3026.
23.
VasudevaPMadersbacherH. Factors implicated in pathogenesis of urinary tract infections in neurogenic bladders: some revered, few forgotten, others ignored. Neurourol Urodyn2014; 33(1): 95–100.
24.
FowlerCJPanickerJNDrakeM, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry2009; 80(5): 470–477.
25.
GallienPNicolasBRobineauS, et al. Urological complications in multiple sclerosis: study of risk factors. Ann Readapt Med Phys1998; 41(3): 155–158.
26.
BerryREKlumppDJSchaefferAJ. Urothelial cultures support intracellular bacterial community formation by uropathogenic Escherichia coli. Infect Immun2009; 77(7): 2762–2772.
27.
GoetzLLKlausnerAP. Strategies for prevention of urinary tract infections in neurogenic bladder dysfunction. Phys Med Rehabil Clin N Am2014; 25(3): 605–618.
28.
DevilleWLYzermansJCvan DuijnNP, et al. The urine dipstick test useful to rule out infections. A meta-analysis of the accuracy. BMC Urol2004; 4: 4.
29.
EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam, the Netherlands, 2022.
30.
WyndaeleJJBraunerAGeerlingsSE, et al. Clean intermittent catheterization and urinary tract infection: review and guide for future research. BJU Int2012; 110(11 Pt C): E910–E917.
31.
MortonSCShekellePGAdamsJL, et al. Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. Arch Phys Med Rehabil2002; 83(1): 12938.
32.
SalomonJDenysPMerleC, et al. Prevention of urinary tract infection in spinal cordinjured patients: safety and efficacy of a weekly oral cyclic antibiotic (WOCA) programme with a 2 year follow-up–an observational prospective study. J Antimicrob Chemother2006; 57(4): 784–788.
33.
CorrealeJFiolMGilmoreW. The risk of relapses in multiple sclerosis during systemic infections. Neurology2006; 67(4): 652–659.
34.
CanibañoBDeleuDMesraouaB, et al. Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations. J Drug Assess2020; 9(1): 20–36.
35.
WinkelmannALoebermannMReisingerEC, et al. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol2016; 12(4): 217–233.
36.
LucioAD’AnconaCAPerissinottoMC, et al. Pelvic floor muscle training with and without electrical stimulation in the treatment of lower urinary tract symptoms in women with multiple sclerosis. J Wound Ostomy Continence Nurs2016; 43(4): 414–419.
37.
De RidderDVan Der AaFDebruyneJ, et al. Consensus guidelines on the neurologist’s role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis. Clin Neurol Neurosurg2013; 115(10): 2033–2040.
38.
SadiqABruckerBM. Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients. Curr Urol Rep2015; 16(7): 44.
39.
AharonySMLamOCorcosJ. Treatment of lower urinary tract symptoms in multiple sclerosis patients: review of the literature and current guidelines. Can UrolAssoc J2017; 11(3–4): E110–E115.
40.
CetinelBTarcanTDemirkesenO, et al. Management of lower urinary tract dysfunction in multiple sclerosis: a systematic review and Turkish consensus report. Neurourol Urodyn2013; 32(8): 1047–1057.
41.
LapidesJDioknoACSilberSJ, et al. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol1972; 107(3): 458–456.
42.
HollingsworthJMRogersMAKreinSL, et al. Determining the noninfectious complications of indwelling urethral catheters: a systematic review and meta-analysis. Ann Intern Med2013; 159(6): 401–410.
43.
GallienPAmarencoGBenoitN, et al. Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: a multicenter, randomized, placebo-controlled, double-blind trial. Mult Scler J2014; 20(9): 1252–1259.
44.
BouckaertJBerglundJSchembriM, et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol2005; 55(2): 441–455.
45.
KranjčecBPapešDAltaracS. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol2014; 32(1): 79–84.
46.
FoutsDEPieperRSzpakowskiS, et al. Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. J Transl Med2012; 10: 174.
47.
LeeBSBBhutaTSimpsonJM, et al. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev2012; 10: CD003265.
48.
CostantiniELazzeriMPistolesiD, et al. Morphological changes of bladder mucosa in patients who underwent instillation with combined sodium hyaluronic acid-chondroitin sulphate (Ialuril®). Urol Int2013; 91(1): 81–88.
49.
DarouicheROGreenBGDonovanWH, et al. Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder. Urology2011; 78(2): 341–346.
50.
HorwitzDMcCueTMapesAC, et al. Decreased microbiota diversity associated with urinary tract infection in a trial of bacterial interference. J Infect2015; 71: 358–367.
51.
SlimESmitCABosAJ, et al. Nosocomial transmission of highly resistant microorganisms on a spinal cord rehabilitation ward. J Spinal Cord Med2009; 32(4): 422–427.
52.
NealDE. Host defense mechanisms in urinary tract infections. Urol Clin North Am1999; 26(4): 677–686, vii.
53.
DelnayKMStonehillWHGoldmanH, et al. Bladder histological changes associated with chronic indwelling urinary catheter. J Urol1999; 161(4): 1106–1108; discussion 1108–1109.
54.
LinsenmeyerTAOakleyA. Use of empiric antibiotics to treat symptomatic UTI in SCI individuals- NIDILRR SCI Model Systems study (personal communication).
55.
Niël-WeiseBSvan den BroekPJda SilvaEM, et al. Urinary catheter policies for long-term bladder drainage. Cochr Database Syst Rev2012; 8: CD004201.
56.
PoirierCDinhASalomonJ, et al. Antibiotic cycling prevents urinary tract infections in spinal cord injury patients and limits the emergence of multidrug resistant organ-ism. J Infect2015; 71: 491–493.
57.
PrietoJMurphyCLMooreKN, et al. Intermittent catheterisation for long-term bladder management. Cochrane Database Syst Rev2014; 9: CD006008.
58.
LinsenmeyerTALinsenmeyerMA. Urinary bacterial flora in SCI patients with symptomatic urinary tract infections. J Spinal Cord Med2014; 37(4): 469.
59.
CardenasDDHoffmanJM. Hydrophilic catheters versus noncoated catheters for reducing the incidence of urinary tract infections: a randomized controlled trial. Arch Phys Med Rehabil2009; 90(10): 1668–1671.
60.
SalamehAMohajerMADarouicheRO. Prevention of urinary tract infec-tions in patients with spinal cord injury. Can Assoc Med2015; 187: 807–811.
61.
McClurgDBuggeCEldersA, et al. Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: results of the COSMOS mixed-methods study. Mult Scler J2019; 25(5): 727–739.
62.
LuotoEJussilainenMSandellS. Intermittent self-catheterization in multiple sclerosis. Sairaanhoitaja1993; 1: 17–20.
63.
TornicJPanickerJN. The management of lower urinary tract dysfunction in multiple sclerosis. Curr Neurol Neurosci Rep2018; 18(8): 54.
64.
Castel-LacanalEGameXDe BoissezonX, et al. Impact of intermittent catheterization on the quality of life of multiple sclerosis patients. World J Urol2013; 31(6): 1445–1450.
65.
CampetellaMMarinoFGaviF, et al. Classification and management of sexual dysfunctions in multiple sclerosis patients: a review of current literature. Urologia2023; 90(4): 605–610.
66.
YeDChenYJianZ, et al. Catheters for intermittent catheterization: a systematic review and network meta-analysis. Spinal Cord2021; 59(6): 587–595.
67.
NseyoUSantiago-LastraY. Long-term complications of the neurogenic bladder. Urol Clin North Am2017; 44(3): 355–366.
68.
McGuireEJWoodsideJRBordenTA, et al. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol2002; 167(2): 1049–1053.
69.
SirlsLZimmernPLeachG. Role of limited evaluation and agressive medical management in multiple sclerosis: a review of patients. J Urol1994; 151: 946–950.
70.
GiannantoniAScivolettoGDi StasiSM, et al. Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. Neurourol Urodyn1998; 17(2): 89–98.
71.
AmarencoGBoscSBoiteauF. Les complications urologiques de la sclérose en plaques. 180 cas [Urologic complications of multiple sclerosis. 180 cases]. Presse Med1996; 25(22): 1007–1010.
72.
BartSDe SèzeMChartier-KesslerE, et al. Prise en charge urologique des vessies neurogènes : les pathologies en neurourologie: Chapitre C: troubles vésico-sphinctériens et sclérose en plaques. Prog Urol2007; 17: 358–364.
73.
IneichenBVSchneiderMPHlavicaM, et al. High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis. Mult Scler J2018; 24: 529–534.
74.
AverbeckMAMadersbacherH. Follow-up of theneuro-urological patient: a systematic review. BJU Int2015; 115(S6): 39–46.
75.
AbramsPCardozoLKhouryS, et al (eds) Incontinence. International consultation on urological diseases and european association of urology. 5th ed. 2014; 827–1000.
76.
ChikkalingaiahKBMGrantNDMangoldTM, et al. Performance of simplified modification of diet in renal disease and Cockcroft-Gault equations in patients with chronic spinal cord injury and chronic kidney disease. Am J Med Sci2010; 339(2): 108–116.
77.
WaitesKBCanuppKCDeVivoMJ, et al. Compliance with annual urologic evaluations and preservation of renal function in persons with spinal cord injury. J Spinal Cord Med1995; 18(4): 251–254.
78.
ZhangZLiaoL. Risk factors predicting upper urinary tract deterioration in patients with spinal cord injury: a prospective study. Spinal Cord2014; 52(6): 468–471.
79.
WeldKJDmochowskiRR. Effect of bladder management on urological complications in spinal cord injured patients. J Urol2000; 163(3): 768–772.
80.
FeiferACorcosJ. Contemporary role of suprapubic cystostomy in treatment of neuropathic bladder dysfunction in spinal cord injured patients. Neurourol Urodyn2008; 27(6): 475–479.
81.
De SezeMRuffionADenysP, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler2007; 13(7): 915–928.
